MedPath
TGA Approval

CABENUVA cabotegravir 400 mg/2 mL plus rilpivirine 600 mg/2 mL prolonged-release suspensions for injection vials (323784)

323784

CABENUVA cabotegravir 400 mg/2 mL plus rilpivirine 600 mg/2 mL prolonged-release suspensions for injection vials

ViiV Healthcare Pty Ltd

February 23, 2021

Medicine

Medicine

Active

Registered

Product Information

Consumer Medicine Information

https://medical-cdn.nocode.com/drug_tga/daf6903dda2657a6b055c446e9f2d683.pdf

Product Information

https://medical-cdn.nocode.com/drug_tga/1f89b9712273adf7da30e6423fdb0297.pdf

Active Ingredients

cabotegravir

rilpivirine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

CABENUVA cabotegravir 400 mg/2 mL plus rilpivirine 600 mg/2 mL prolonged-release suspensions for injection vials (323784) - TGA 批准文号 | MedPath